Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.
Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research. The company offers instrument systems as well as consumable reagents and software tools that enable end-to-end proteomic workflows, from sample preparation through data analysis. By focusing on single-molecule detection, Nautilus aims to reveal low-abundance proteins that are often missed by bulk analysis methods.
Nautilus went public in 2021, listing on the Nasdaq under the ticker symbol NAUT, and has since forged collaborations with leading research centers and biotech partners. Its management team brings together experts in biochemistry, engineering and data science, with experience in both academic research and commercial biotechnology. The company continues to expand its R&D capabilities and manufacturing infrastructure to support broader adoption of its proteomics platform.
Looking ahead, Nautilus Biotechnology plans to scale its instrument deployments and refine its analytical software to address emerging challenges in precision medicine and biomarker discovery. By delivering comprehensive proteomic profiles with increased depth and accuracy, the company seeks to empower scientists and clinicians with the tools needed to understand complex diseases and develop novel therapeutics.
AI Generated. May Contain Errors.
